The synovial fluid neuropeptide PACAP may act as a protective factor during disease progression of primary knee osteoarthritis and is increased following hyaluronic acid injection

Innate Immun. 2019 May;25(4):255-264. doi: 10.1177/1753425919839125. Epub 2019 Apr 1.

Abstract

The correlation of serum and synovial fluid (SF) pituitary adenylate cyclase-activating polypeptide (PACAP) levels with disease progression of primary knee osteoarthritis (OA) was explored. Radiographic severity of OA was determined by Kellgren-Lawrence (K-L) grades. PACAP levels were measured by ELISA before treatment, and 4 and 8 wk following hyaluronic acid (HA) injection. Levels of IL-1β and MMP-3 were also detected. The numeric pain scale (NPS), revised Oxford Knee Score (OKS), and American Knee Society Score (AKSS) were employed to evaluate to symptomatic severity. Receiver-operating-characteristic (ROC) curve analysis was carried out to compare the diagnostic value of PACAP, IL-1β, and MMP-3 for the K-L grade. PACAP concentrations in SF but not serum were significantly lower in OA patients compared with controls. SF PACAP levels were negatively associated with K-L grades and higher NPS as well as worse AKSS and OKS. Further analysis demonstrated that PACAP concentration in SF was negatively correlated with expressions of IL-1β as well as MMP-3 and may act as a marker for radiographic progression along with MMP-3. Last, we found SF PACAP levels exhibited an incremental trend after HA injection. These findings confirmed the crucial role of PACAP deficiency in the development of primary knee OA.

Keywords: Pituitary adenylate cyclase-activating polypeptide; disease progression; hyaluronic acid injection; knee osteoarthritis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cartilage, Articular / diagnostic imaging*
  • Disease Progression
  • Female
  • Humans
  • Hyaluronic Acid / metabolism
  • Interleukin-1beta / genetics
  • Interleukin-1beta / metabolism
  • Male
  • Matrix Metalloproteinase 3 / metabolism
  • Middle Aged
  • Neuroprotective Agents / metabolism*
  • Osteoarthritis, Knee
  • Pituitary Adenylate Cyclase-Activating Polypeptide / metabolism*
  • Synovial Fluid / metabolism*
  • Synoviocytes / metabolism*

Substances

  • Interleukin-1beta
  • Neuroprotective Agents
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Hyaluronic Acid
  • Matrix Metalloproteinase 3